Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease which may have significant impacts on quality of life. While patients with skin of color (SOC) have a higher prevalence of AD, greater severity, and longer disease persistence, these patients are often underrepresented in clinical trials. As such, improved clinical trial diversity and real-world case reports are necessary to help reduce health inequity and improve treatment understanding and access for all patient populations. Here, we present cases of 2 biologic-naive, SOC patients with moderate-to-severe AD who were successfully treated with the targeted biologic, tralokinumab. These results highlight the rapid onset of action of tralokinumab in SOC patients, and the improvement of the difficult-to-treat head and neck subtype and hyperpigmentation on the hands.
No takes yet. Share an insight, caveat, or question.
Tinker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: